Further analysis suggests that it may be due to the positive correlation between ZFHX3 mutation and the previously mentioned immunotherapy biomarkers, such as TILs, TMB, DDR pathway in NSCLC, etc. At the same time, the study revealed that activated CD4 + T cells, dendritic cells (DCs) and M1 macrophages were more abundant in ZFHX3 mutated LUAD patients. This evidence concerns the gene ZFHX3 and non-small cell lung carcinoma.